Status:
COMPLETED
Study Of Dalbavancin Drug Levels Achieved In Hospitalized Adolescents Who Are Receiving Antibiotic Therapy For Bacterial Infections
Lead Sponsor:
Pfizer
Conditions:
Bacterial Infections
Eligibility:
All Genders
12-17 years
Phase:
PHASE1
Brief Summary
Adolescent subjects hospitalized for the treatment of bacterial infections will be given 1 gram of dalbavancin through their veins and levels of dalbavancin in blood and urine will be measured at diff...
Eligibility Criteria
Inclusion
- 12 to 17 year old adolescents hospitalized for the treatment of bacterial infections.
Exclusion
- Patients being treated with vancomycin.
- Patients with liver and kidney failure.
- Pregnant female subjects.
Key Trial Info
Start Date :
September 1 2008
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2009
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00678106
Start Date
September 1 2008
End Date
July 1 2009
Last Update
October 12 2009
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
San Diego, California, United States, 92123
2
Pfizer Investigational Site
Louisville, Kentucky, United States, 40202
3
Pfizer Investigational Site
Cleveland, Ohio, United States, 44106